| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
LONDON and NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter e... |
| 23 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Dire... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia |
| 07 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
| 15 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, MeiraGTx Holdings plc (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). A total of 75,326,022 of the Company’s ordinary shares were present in person or represented by proxy at the ... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
-Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 |
| 24 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
| 16 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
11,111,111 ordinary shares, nominal value $0.00003881 per share |
| 16 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
| 16 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia |
| 26 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and... |
| 02 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
-Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited... |
| 10 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential Biologics Lice... |
| 26 Jun 2025 |
8-K: Regulation FD Disclosure
MeiraGTx Holdings plc (the “Company”) has received the clearances and approvals under the foreign direct investment laws of the United Kingdom that are applicable to the proposed transactions the Company entered into with Hologen Limited... |
| 17 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, MeiraGTx Holdings plc (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). A total of 59,311,935 of the Company’s ordinary shares were present in person or represented by proxy at the ... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
-Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus... |
| 09 May 2025 |
8-K: Regulation FD Disclosure
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease |
| 04 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On March 31, 2025, MeiraGTx, LLC (“Tenant”), a Delaware limited liability company and a wholly-owned subsidiary of MeiraGTx Holdings plc, entered into a Lease Agreement (the “Lease”) with ARE-East River Science Park, LLC (the “Landlord”)... |
Loading...